Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8211880 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(4 years from now) | |
US8128960 | NOVARTIS | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(5 years from now) |
Market Authorisation Date: 29 November, 2007
Treatment: Visualization during vitrectomy procedures; Treatment of ophthalmic disorders
Dosage: INJECTABLE;INTRAVITREAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8636713 | BAUSCH AND LOMB INC | Methods and devices for drug delivery to ocular tissue using microneedle |
May, 2027
(3 years from now) | |
US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(9 years from now) | |
US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Oct 22, 2024 |
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8828440 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(7 years from now) | |
US9555048 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(7 years from now) |
Market Authorisation Date: 06 October, 2017
Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR